Search PubMed⌕ Search

Biomedical subjects

T Takashima

Publications and source records attributed to T Takashima.

At least 361 records · Page 20Linked to original sources
PubMed1983

[Diagnosis and treatment of primary lung carcinoma--CT diagnosis of N-factor].

We applied CT to the diagnosis of the intrathoracic lymph nodes metastases from the lung carcinoma. We defined nodes with a diameter larger than 1 cm as indicating presence of metastasis. In the diagnosis of the mediastinal lymph nodes metastases, the overall accuracy was 61%. There were many over-estimations in epidermoid carcinomas and some under--estimations in adenocarcinomas because of the presence of inflammatory hyperplastic nodes in the former and several small metastatic nodes in the latter. In the diagnosis of the hilar lymph nodes metastases, the CT detectability of the positive nodes was low. There were many under-estimations because of the presence of small metastatic nodes in adenocarcinomas and difficulty of separating the nodes from the primary tumors in epidermoid carcinomas. In the diagnosis of the intrathoracic lymph nodes metastases, CT is useful to decrease under-estimations, but is apt to increase some over-estimations. We should make a further evaluation for the relationship between the lymph nodes size, location and histology of primary tumors.

Adenocarcinoma↗
PubMed1983

[Laboratory and clinical studies of T-1982 (cefbuperazone in pediatric field].

The authors have carried out the laboratory and clinical studies of T-1982 (cefbuperazone). The results were as follows: The sensitivity was estimated by the plate dilution method on 28 strains of S. aureus 26 strains of E. coli, 27 strains of K. pneumoniae, 25 strains of S. marcescens and 14 strains of Proteus sp. isolated from patients. The distribution of susceptibility of S. aureus was 1.25-25 micrograms/ml and the peak of distribution was 12.5 micrograms/ml. The strains of 84.6% of E. coli were inhibited at concentration of less than 0.39 micrograms/ml. The strains of 77.8% of K. pneumoniae were inhibited at concentration of less than 0.2 microgram/ml. The strains of 96% of S. marcescens was inhibited at concentration of less than 3.13 micrograms/ml. The distribution of susceptibility of Proteus sp. was 0.39-25 micrograms/ml. T-1982 was given to intravenous administration for 5 minutes and drip infusion for 30 minutes a single dose of 20 mg/kg of T-1982 to 2 and 2 children respectively. After intravenous administration of T-1982, the mean serum level was peak 88.4 +/- 8.7 micrograms/ml at 15 minutes, 52.5 +/- 2.7 micrograms/ml at 1 hour, 4.6 +/- 0.15 micrograms/ml at 6 hours respectively. Half-life was 89 minutes. And after drip infusion of T-1982, the mean serum level was 75.5 +/- 3.5 micrograms/ml at 30 minutes and 3.1 +/- 0.6 micrograms/ml at 6.5 hours respectively. Half-life was 82 minutes. The mean urinary excretion rate was 94.7%, 57.4 +/- 11.0% up to 6 hours after intravenous administration and drip infusion respectively. T-1982 was effective in 13 cases out of 13 cases with bacterial infections. No side effects were observed except for 1 case with elevation of serum GOT, 1 case with elevation of serum GPT and 2 cases with eosinophilia.

Anti-Bacterial Agents↗
PubMed1983

[Pharmacological evaluation of an ampicillin suppository (KS-R1) in acute respiratory tract infection in children: a comparison with an oral form of ampicillin].

A comparative well-controlled study was performed to evaluate the efficacy and tolerability of ampicillin rectal suppository (KS-R1) compared with those of oral form of ampicillin (ABPC) against acute respiratory tract infections in pediatric field. KS-R1 at the dose of 125 mg X 4/day of ABPC in potency, or the oral form at the same dosage, was given to 166 cases of patients with acute respiratory tract infection due to Streptococcus pyogenes, Streptococcus pneumoniae or Haemophilus influenzae for 7 days, as a rule. The clinical efficacy rates evaluated in 151 cases (KS-R1 group in 77 cases, oral group in 74 cases) on standard criteria of committee members were 88.3% for the KS-R1 group and 86.5% for the oral group, respectively. There was no significant difference between 2 groups. Evaluation by stratification according to the diagnosis showed that the efficacy rates for the KS-R1 group and for the oral group were 87.5% and 85.0% against pharyngitis, 90.5% and 90.0% against tonsillitis and 84.2% and 78.6% against bronchitis, respectively. None of them showed significant difference between 2 groups. The bacteriological effect was evaluated in 55 cases (KS-R1 group in 33 cases, oral group in 22 cases), and disappearance rate was 93.9% for the KS-R1 group and 95.5% for the oral group, showing no significant difference. Side effect including subjective and objective symptoms were strictly evaluated in 163 cases (KS-R1 group in 83 cases, oral group in 80 cases), but the incidence rate which was 22.9% for the KS-R1 group and 23.8% for the oral group showed no significant difference. The above results indicate that against acute respiratory tract infections in pediatric field, KS-R1 possesses clinical efficacy and safety similar to the oral form of ABPC, and that it is a useful suppository.

Acute Disease↗
PubMed1983

[Experimental and clinical evaluation of cefotetan in pediatrics].

The authors have carried out the laboratory and clinical studies of cefotetan (CTT), and obtained the following results. The antibacterial activities of CTT were measured by the plate dilution method against the clinical isolates of S. aureus, E. coli, K. pneumoniae, S. marcescens and Salmonella sp. The susceptibility distribution of S. aureus to CTT was at concentration of 6.25-12.5 micrograms/ml and the peak of that was obtained at 6.25 micrograms/ml with an inoculum size of 10(6) cells/ml. And the peaks of susceptibility distribution of E. coli and K. pneumoniae to CTT were obtained at less than 0.1 microgram/ml respectively, and that of S. marcescens was obtained at 6.25-12.5 micrograms/ml with an inoculum size of 10(6) cells/ml. The growth of all strains of Salmonella sp. was inhibited at concentration of less than 0.1 microgram/ml. As for pharmacokinetic study, CTT was given by intravenous bolus injection and drip infusion for 30 minutes at a single dose of 20 mg/kg. After intravenous bolus injection of 20 mg/kg of CTT, the mean peak serum level was 175.0 +/- 7.0 micrograms/ml at 15 minutes after injection, and half-life time was 3.53 hours. After 30 minutes drip infusion of 20 mg/kg of CTT, the mean serum concentration was 106.0 +/- 6.0 micrograms/ml at end of infusion, half-life time was 2.41 hours. The mean urinary excretion rates were 49.4% and 64.2% up to 8 hours after drip and bolus injection of 20 mg/kg of CTT, respectively. CTT was given 15 cases with bacterial infection. Daily doses of CTT were from 15.0 to 107.0 mg/kg. Clinical results obtained were excellent and good responses in 12 of 15 cases (80.0%). No side effects were obtained except for 2 cases with elevation of GOT and GPT, and 1 case with eosinophilia.

Age Factors↗
PubMed1983

Computed tomographic diagnosis of strangulated obstruction.

A case of strangulated obstruction with computed tomographic appearance is reported. CT may be useful for the demonstration of the strangulated loop in a patient with obstructive symptoms and a soft tissue mass in the pelvis shown on plain films of the abdomen.

Abdominal Neoplasms↗
PubMed1983

[Experimental and clinical evaluation of an ampicillin suppository (KS-R1)].

The basic and clinical studies of ampicillin suppository (KS-R1) in pediatric infections were carried out, and the following results were obtained: For study of absorption and excretion of KS-R1, a single dose of 250 mg of KS-R1 was administered to 3 cases. The mean serum levels were obtained 4.10 +/- 1.55 micrograms/ml at 30 minutes, and 1.52 +/- 0.25 micrograms/ml, 0.38 +/- 0.04 micrograms/ml at 1 and 2 hours after rectal administration, respectively. The serum levels were not detectable after 4 hours in all cases. The half lives were 0.39, 0.54 hour and 0.44 hour, respectively. The mean urinary excretion rate to 6 hours was 14.8%. Clinical efficacy was evaluated in 17 cases with tonsillitis (15 cases), bronchitis (1 case) and scarlet fever (1 case). Good responses were obtained in 15 of 17 cases (88.2%). Bacteriological response in the form of eradication was noted in 4 of 5 cases. Side effects were examined with all of the 19 cases, and eosinophilia was observed in 1 case.

Age Factors↗
PubMed1983

[Experimental and clinical evaluation of cefpiramide in pediatrics].

The authors have carried out the laboratory and clinical studies of cefpiramide (CPM). The results were as follows; The sensitivity was estimated by plate dilution method on 27 strains of S. aureus and P. aeruginosa, 26 strains of E. coli, 25 strains of K. pneumoniae and 13 strains of Proteus sp. isolated from patients. The distribution of S. aureus was 0.78 approximately 6.25 micrograms/ml and the peak of distribution was 1.56 micrograms/ml. The distribution of E. coli was 0.78 approximately 50 micrograms/ml and the peak of distribution was 0.78 and 25 micrograms/ml. The growth of 24% of K. pneumoniae was not inhibited at concentration of more than 50 micrograms/ml. The distribution of Proteus sp. was 6.25 approximately 100 micrograms/ml. The growth of 77.8% of P. aeruginosa was inhibited at concentration of less than 3.13 micrograms/ml. CPM was given by intravenous administration for 5 minutes and drip infusion for 30 minutes at a single dose of 20 mg/kg of CPM to each 2 children respectively. After intravenous administration of CPM, the mean peak serum level was 200.5 +/- 37.5 micrograms/ml at 15 minutes, 44.3 +/- 0.9 micrograms/ml at 6 hours, 19.9 +/- 0.3 micrograms/ml at 12 hours respectively. Half-life time was 4.2 hours. After drip infusion of CPM, the mean peak serum level was 150.5 +/- 14.5 micrograms/ml at end of infusion, 23.6 +/- 3.3 micrograms/ml at 6 hours and 8.2 +/- 2.0 micrograms/ml at 12 hours respectively. Half-life time was 3.8 hours. The mean urinary excretion rate was 23.15%, 28.2% up to 12 hours after intravenous administration and drip infusion respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Age Factors↗
PubMed1983

[Pharmacokinetic and clinical studies of latamoxef in newborn and premature infants].

The authors have carried out the pharmacokinetic and clinical studies of latamoxef (LMOX) in mature and premature neonates. The results were as follows. The serum mean peak levels of LMOX after intravenous administration at a single dose of 10 mg/kg (20 mg/kg) were 40.7 +/- 20.8 (76.6 +/- 12.7) micrograms/ml in 1 to 3 day-old-neonates, 39.3 +/- 29.3 (52.5 +/- 6.6) micrograms/ml in 4 to 7 day-old-neonates and 26.0 +/- 2.1 (47.4) micrograms/ml in 8 to 15 day-old neonates at 15 minutes. The serum mean levels at 6 hours after dosage were 12.5 +/- 5.2 (25.6 +/- 9.2) micrograms/ml, 10.3 +/- 5.3 (11.8 +/- 1.6) micrograms/ml and 4.2 +/- 0.9 (7.2) micrograms/ml, respectively. The mean half-life times were 4.25 (6.0) hours in 1 to 3 day-old-neonates, 3.4 (3.3) hours in 4 to 7 day-old-neonates and 2.2 (2.2) hours in 8 to 15 day-old-neonates. The serum levels of LMOX after intravenous drip infusion for 30 minutes at a single dose of 10 mg/kg were 17.6 micrograms/ml at completion of infusion, 6.9 micrograms/ml at 6.5 hours, and the half-life was 3.8 hours in 2 day-old-mature neonates. In 3 day-old-premature neonates, the serum levels were 21.1 micrograms/ml at the completion of infusion, 12.7 micrograms/ml at 6.5 hours, and the half-life was 12.2 hours. After intravenous drip infusion for 30 minutes a single dose of 20 mg/kg of LMOX the serum mean levels were 58.5 +/- 6.4 micrograms/ml at the completion of infusion, 19.3 +/- 1.1 micrograms/ml at 6.5 hours, respectively. The half-life times were 4.0 hours in 2 day-old-neonates and 4.5 hours in 4 day-old-neonates. The urinary excretion rate of LMOX in 3 day-old-neonate was 31.7% up to 6 hours after intravenous administration at a single dose of 10 mg/kg. LMOX were clinically effective in a case of pneumonia, but not effective in a case of septicemia. No side effect was observed except for 1 case with elevation of GOT.

Bacterial Infections↗
PubMed1982

Hepatocellular carcinoma involving the portal vein.

A case of hepatocellular carcinoma with invasion of the portal vein is reported. A tumor defect within the dilated portal vein is well demonstrated by computed tomography, and its appearance is compatible with the "thread and streaks" sign seen on hepatic angiography.

Angiography↗